In March 2023, Ad Scientiam, a leader in digital biomarkers, announced the launch of the ME&MGopen study in partnership with Alexion. This fully decentralized study will enable patients to provide data and participate in medical innovation from the comfort of their homes. 175 patients have already been recruited in the United States and 11 in Canada.
English 
French